Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026)
Galectin Therapeutics (GALT) posted quarterly Preferred Stock Liabilities of $1.7 million for Q1 2026, little changed year-over-year from $1.7 million in Q1 2025, and little changed quarter-over-quarter from $1.7 million in Q4 2025.
Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Preferred Stock Liabilities history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (changed 0.0% YoY), while the FY2025 annual figure was $1.7 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q1 2026 stood at $1.7 million, roughly flat from $1.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $1.7 million in Q1 2022, with the low at $1.7 million in Q1 2022.
- The 5-year median for Preferred Stock Liabilities is $1.7 million (2022), against an average of $1.7 million.
- Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
- Galectin Therapeutics' Preferred Stock Liabilities stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
- Business Quant data shows GALT's Preferred Stock Liabilities at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | 1.72 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 1.72 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 1.72 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.72 Mn |
| Jun 30, 2021 | 1.72 Mn |